Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Capecitabine Maintenance in mCRC
NCT05016869Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05016869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016869.